Urticaria | Unmet Need | Chronic Inducible and Chronic Spontaneous | US/EU | 2020
The urticaria drug market is dominated by oral medications, including steroids and second-generation, nondrowsy antihistamines, prescribed for both chronic inducible and chronic spontaneous urticaria. However, both drug classes have serious side effects, and many patients still struggle to control their lesions. As a result, the approval of Xolair has been welcomed by physicians and patients. Clinical trials for additional biological therapies are underway, capturing urticaria disease data using an array of clinical scoring systems. With only one biological drug currently approved, the most important factors for driving prescribing decisions remain unknown, and many of the unmet needs in this market remain unfulfilled.
Questions answered
- What unmet needs remain for chronic urticaria patients after the approval of Xolair?
- Which clinical trial endpoints and nonclinical attributes are key influencers on dermatologists’ and allergists’ prescribing decisions and which have limited impact? What are potential areas of hidden opportunity?
- How does Xolair (Novartis / Genentech), approved for chronic idiopathic urticaria in the United States, perform on key treatment drivers and goals? How does its performance compare with that of frequently prescribed conventional therapies, including steroids and antihistamines?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European dermatologists and allergists for a hypothetical new chronic urticaria drug?
Product description
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 U.S. and 30 European allergists and dermatologists fielded in February 2020
Key companies: Genentech, Novartis
Key drugs: Xolair, ligelizumab, steroids, antihistamines
